Biologic control of injury and inflammation: Much more than too little or too late

World Journal of Surgery

Volumn 20, Issue 4, 1996, Pages 437-446

  Guirao, Xavier ^a   Lowry, Stephen F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; NORADRENALIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

BACTEREMIA; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INFLAMMATION; INJURY; MEDIATOR RELEASE; NONHUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TISSUE INJURY; TISSUE REPAIR; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS; CRITICAL CARE; CYTOKINES; HOMEOSTASIS; HUMANS; IMMUNOCOMPETENCE; INFLAMMATION MEDIATORS; MULTIPLE ORGAN FAILURE; MULTIPLE TRAUMA; SURVIVAL RATE; TREATMENT OUTCOME; WOUND HEALING;

EID: 0029932695     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900069     Document Type: Review

References (135)

1. Fisher, C.J., Opal, S.O., Dhainaut, J.F., et al.: Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. 21:318, 1993
2. Abraham, E., Wundernik, R., Silverman, H., et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double blind multicentric clinical trial. J.A.M.A. 273:934, 1995
3. Fisher, C.J., Slotman, G.J., Opal. S.M., et al.: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open label, placebo controlled multicentric trial. Crit. Care Med. 22:12, 1994
4. Fisher, C.J., Dhainaut, J-F.A., Opal, S.M., et al.: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. J.A.M.A. 271:1836, 1994
5. Sadoff, J.C.: Soluble TNF receptors. Presented at the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches, Munich, 1994
6. Fong, Y., Moldawer, L.L., Shires, T., Lowry, S.L.: The biologic characteristics of cytokines and their implication in surgical injury. Surg. Gynecol. Obstet. 170:364, 1990
7. Mancilla, J., Garcia, P., Dinarello, C.: The interleukin-1 receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect. Immun. 67:926, 1993
8. Luger, A., Graf, H., Swarz, H.P , Stummvoll, H.K., Luger, T.A.: Decreased serum IL-1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit. Care Med. 14.458, 1986
9. Schmand, J.F., Ayala, A., Morrison, M.H., Chaudry, I H.: Effects of hydroxyethyl starch after trauma hemorragic shock: restoration of macrophage integrity and prevention of increased circulating interleukin-6. Crit. Care Med. 23-806, 1995
10. Chaudry, I.H., Ayala, A., Ertel, W., Stephan, R.N.: Hemorrhage and resuscitation: immunological aspects. Am. J. Physiol. 259:R663, 1990
11. Meldrum, D.R., Ayala, A., Perrin, M.M., Ertel, W., Chaudry, I.H.: Diltiazen restores IL-2. IL-3, II-6 and IFN-gamma synthesis and decreased host susceptibility to sepsis following hemorrage. J. Surg. Res. 51:158, 1991
12. Fabian, T.C., Croce, M.A., Fabian, M.J., et al.: Reduced tumor necrosis factor production in endotoxin-spiked whole blood after trauma: experimental results and clinical correlation. Surgery 118:63, 1995
13. Faist, E., Kupper, T.S , Baker, C.C., Chaudry, I.H., Dwyer, J., Baue, A.E.: Depression of cellular immunity after major injury: its associ-ation with posttraumatic complications and its reversal with immunomodulation. Arch. Surg. 121:1000, 1986
14. Browder, W., Williams, D., Pretus, H., et al.: Beneficial effect of enhanced macrophage function in the trauma patient. Ann. Surg. 211:605, 1990
15. Dominioni, L., Dionigi, R., Zanello, M., et al.: Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch. Surg. 126:236, 1991
16. Polk, H.C., Cheardle, W.G., Livingstone, D.H., et al.: A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am. J. Surg. 163:191, 1992
17. Lowry, S.F.: Immunotherapy of sepsis: the role of cytokine mediators and the potential for attenuation of their activity. In Critical Care. State of the Art, D.S. Prough, R.J. Traysman, editors. Society of Critical Care Medicine, Anaheim, CA, USA, 1993, pp. 109-130
18. Lowry, S.F.: Cytokines mediators of immunity and inflammation. Arch. Surg. 128:1235, 1993
19. Exley, A.R., Cohen, J., Buurman, W., et al.: Monoclonal antibody to TNF in severe septic shock. Lancet 335.1275, 1990
20. Marano, M.A., Moldawer, L.L., Fong, Y., et al.: Cachectin/TNF production in experimental burns and Pseudomonas infection. Arch. Surg. 123-1383, 1988
21. Keogh, C., Fong, Y., Marano, M., et al.: Identification of a novel tumor necrosis factor alpha cachectin from the livers of burned and infected rats. Arch. Surg. 125:79, 1990
22. Giroir, B.P., Horton, J.W., White, D.J., McInryre, K.L.: Inhibition of tumor necrosis factor prevents myocardial dysfunction during burn shock. Am. J. Physiol. 267:H118, 1994
23. Waage, A., Halstensen, A , Espevik, T.: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355, 1987
24. Mustafa, M.M., Lebel, M.H., Ramilo, O., Resisch, J.S., Beutler, B., McCracken, G.H.J.: Correlation of interleukin-1 beta and cachectin concentrations in cerebrospinal fluid and outcome from bacterial meningitis. J. Pediatr. 115:208, 1989
25. Girardin, E., Grau, G., Dayer, J.M., et al.: Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. N. Engl. J. Med. 319:397, 1988
26. Debets, J.M., Kampmeijer, R., van der Linden, M.P., Buurman, W.A., van der Linden, C.J.: Plasma tumor necrosis factor and mortality in critically ill patients. Crit. Care Med. 17:489, 1989
27. Rogy, M.A., Coyle, S M , Oldenburg, H.S.A., et al.: Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J. Am. Coll. Surg. 178:132, 1994
28. Casey, L.C., Balk, R.A., Bone, R.C.: Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann. Intern. Med. 119:771, 1993
29. Fischer, E., Marano, M.A., Van Zee, K.J., et al.: Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host respopnse to sublethal endotoxinemia. J. Clin. Invest. 89:1551, 1992
30. Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R., Thompson, R.C.: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 346:550, 1990
31. Alexander, H.R., Doherty, G.M., Buresh, C.M., Venzon, D.J., Norton, J A: A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J. Exp. Med. 173:1029, 1991
32. Barriere, S.L., Lowry, S.F.: An overview of mortality risk prediction in sepsis. Crit. Care Med. 23:376, 1995
33. Dinarello, C.A., Wolff, S.M.: The role of IL-1 in disease. N. Engl. J. Med. 328:106, 1993
34. Kishimoto, T., Akira, S., Taga, T.: Interleukin-6 and its receptor: a paradigm for cytokines. Science 258:593, 1992
35. Akira, S., Hirano, T., Taga, T., Kishimoto, T.: Biology of multifunctional cytokines: IL-6 and related molecules (IL 1, and TNF). FASEB J. 4:2860, 1990
36. Kopf, M., Baumann, H., Freer, G., et al.: Impaired immune and acute-phase responses in interleukin 6-deficient mice. Nature 368: 339, 1994
37. Castell, J.V., Gomez-Lechon, M., David, M., et al.: Interleukin-6 is the major regulator of acute phase response protein synthesis in adult human hepatocytes. FEBS 242:237, 1989
38. Gauldie, J., Northermann, W., Fey, G.H.: IL-6 function as an endocrine hormone in inflammation: Hepatocytes undergoing acute phase response require exogenous IL-6. J. Immunol. 144:3804, 1990
39. Heinrich, P.C., Castell, J.V., Andus, T.: Interleukin-6 and acute phase response. Biochem. J. 265:621, 1990
40. Oldenburg, H.S., Rogy, M.A , Lazarus, D.D., et al. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur. J. Immunol. 23:1889, 1993
41. Mitsuyama, K.: Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 36:45, 1995
42. Helfgott, D.C., May, L.T., Stoeger, Z., Tamm, I., Sehgal, P.B.: Bacterial liposaccharide (endotoxin) enhances expression and secretion of beta 2 interferon by human fibroblasts. J. Exp. Med. 166:1300, 1987
43. Brouckaert, P., Libert, C., Everaerdt, B., Takahshi, N., Cawels, A., Fiers, W.: Tumor necrosis factor, its receptors and the connection with the interleukin-1 and interleukin-6. Immunobiology 187:317, 1993
44. Waage, A., Brandtzaeg, P., Halstensen, A.: The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin-6, interlukin 1 and fatal outcome. J. Exp. Med. 169:333, 1989
45. Hirano, T., Akira, S., Taga, T., Kishimoto, T.: Biological and clinical aspects of IL-6. Immunol. Today 12:443, 1990
46. Calandra, T., Gerain, J., Heumann, D., et al.: High circulating levels of IL-6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokines. Am. J. Med. 91:23, 1991
47. Sessler, C.N., Schwartz, M., Winsor, A.C., Fowler, A.A.: Increased serum cytokines and intracellular adhesion molecule-1 in fulminant Rocky Mountain spotted fever. Crit. Care Med. 23:973, 1995
48. Ayala, A., Wang, P., Ba, Z.F., Perrin, M.M., Ertel, W., Chaudry, I.: Differential alterations in plasma IL-6 TNF levels after trauma and hemorrhage. Am. J. Physiol. 260:R167, 1991
49. Lowry, S.F.: Anticytokine therapies in sepsis. New Horiz. 1:120, 1993
50. Seckinger, P., Isaaz, S., Dayer, J.M.: Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J. Biol. Chem. 20:11966, 1989
51. Engelman, H., Aderka, A., Rubinstein, M., Rotman, D., Wallach, D.: A tumor necrosis factor-binding protein purified to homogeneity from human urine protects from tumor necrosis factor toxicity. J. Biol. Chem. 20:11974, 1989
52. Gatanaga, T., Hwang, C., Khor, W., et al.: Purification and characterization of inhibitor (sTNF receptor) for tumor necrosis factor from serum ultrafiltrates of human cancer patients. Proc. Natl. Acad. Sci U.S.A. 87:8781, 1990
53. Aderka, E., Englemann, H., Hornik, V., et al.: Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51:5602, 1991
54. Heilig, B., Fiehn, C., Brockhaus, M., Gallati, H., Pezzutto, A., Husntein, W., Evaluation of soluble tumor necrosis factor (TNF) receptor antibodies in patients with systemic lupus erythematosus, progressive systemic sclerosis, and mixed connective tissue disease. J. Clin. Immunol. 13:321, 1993
55. Nophar, Y., Kemper, O., Brakebusch, H., et al.: Soluble forms of tumor necrosis factor receptors (TNF-Rs): the cDNA for the type I TNF-R, cloned using aminoacid sequence data of its soluble form, encodes both the cell surface and soluble form of the receptor. EMBO J. 9:3269, 1990
56. Ryffel, B., Mihatsch, M.J.: TNF receptor distribution in human tissues. Int. Rev. Exp. Pathol. 34:149, 1993
57. Heller, R.A., Song, G., Fan, N., Chang, D.J.: The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell 70:47, 1992
58. Tartaglia, L.A., Goeddel, D.V.: Tumor necrosis factor receptor signaling, a dominant negative mutation suppresses the activation of 55 kDa tumor necrosis factor receptor. J. Biol. Chem. 267:4304, 1992
59. Tartaglia, L.A., Pennica, D., Goeddel, D.V.: Ligand passing: the 75 kDa tumor necrosis factor receptor recruits TNF for signaling by the P55 TNF receptor. J. Biol. Chem. 25:18542, 1993
60. Loetscher, H., Stueber, D., Banner, D., Mackay, F., Lesslauer, W.: Human tumor necrosis factor alpha mutants with exclusive specificity for the 55 kd or 75 kd TNF receptors. J. Biol. Chem. 268:26350, 1993
61. Kalthoff, H., Roeder, C., Brockhaust, M., Thiele, H.G., Schmiegfel, W.: Tumor necrosis factor up-regulates the expression of p75 but not p55 TNF receptors and both receptors mediate independently of each other, up regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J. Biol. Chem. 268:2762, 1993
62. Van Zee, K.J., Kohno, T., Fischer, E., Rock, C.S., Moldawer, L.L., Lowry, S.F.: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 89:4845, 1992
63. Cinat, M., Waxman, K., Granger, G.A., Pearce, W., Cheri, A., Daughters, K.: Trauma causes sustained elevation of soluble tumor necrosis factor receptors. J. Am. Coll. Surg. 179:529, 1994
64. Froon, A.H.M., Bemelmans, H.A., Greve, J W., Van der Linden, C.J., Buurman, W.A.: Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit. Care Med. 22:803, 1994
65. Calvano, S.E., Thompson, W.A., Coyle, S.M., Barie, P.S., Moldawer, L.L., Lowry, S.L.: Changes in monocyte and soluble tumor necrosis factor (TNF) receptors during endotoxemia or sepsis. Surg. Forum 44:114, 1993
66. Van der Poll, T., Calvano, S.E., Kunmar, A., et al.: Endotoxin induces down-regulation of functional tumor necrosis factor receptors on circulating monocytes and granulacytes in humans. Blood (in press)
67. Lowry, S.F., Moldawer, S.F., Calvano, S.E.: Cytokine markers of the human response to sepsis. In Year Book of Intensive Care and Emergency Medecine, J.L. Vincent, editor. New York, Springer-Verlag, 1994, pp. 14-24
68. Giri, J., Newton, R.C , Horuk, R.: Identification of soluble interleukin-1 binding protein in cell-free supernatants. J. Biol. Chem. 265:17416, 1990
69. Seckinger, P., Lowenthal, J.W., Williamson, K., Dayers, J.M., MacDonald, R.: A urine inhibitor of interleukin-1 activity that blocks ligand binding. J. Immunol. 139:1546, 1987
70. Hannum, C.H., Wilcox, C.J., Arend, W.P., et al.: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336, 1990
71. Eisenberg, S.P., Evans, R.J., Arend, W.P., et al.: Primary structure and functional expression from complementary DNA of human interleukin-1 receptor antagonist. Nature 343:341, 1990
72. Dripps, D.J., Brandhuber, B.J., Thompson, R.C., Eisenberg, S.P.: Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J. Biol. Chem. 16:10331, 1991
73. Marsh, C.B., More, S.A., Pope, H.A., Wewers, M.D.: IL-1ra suppresses endotoxin-induced IL-1 beta and TNF-alpha release from mononuclear phagocytes. Am. J. Physiol. 267:L39, 1994
74. Fischer, E., Van Zee, K.J., Marano, M., et al.: Interleukin-1 receptor antagonist circulates in experimental inflamation and human disease. Blood 79:2196, 1992
75. Moore, K.W., O'Garra, R., DeWaal Malefyt, R., Vieira, P., Mosmann, T.R.: Interleukin-10. Annu. Rev. Immunol. 11:165, 1993
76. Vieira, P., De Waal Malefyt, R., Dang, M.N., et al.: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading from BCRFI. Proc. Natl. Acad. Sci. U.S.A 88:1172, 1991
77. De Waal Malefyt, R., Abrams, J., Rennet, B., Figdor, C.G., De Vries, J.E.: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autorregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174:1209, 1991
78. Marchant, A., Deviere, B., Byl, B., de Groote, D., Vincent, J.L., Goldman, M.: Interleukin-10 production during septicemia. Lancet 343:707, 1994
79. Derkx, B., Marchant, M., Goldman, R., Bijlmer, R., Van Deventer, S.: High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J. Infect. Dis. 171:229, 1995
80. Durez, P., Abramowicz, C., Gérard, C., et al.: In vivo induction of interleukin-10 by an anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporm. Am. J. Exp. Med. 177:551, 1993
81. Van der Poll, T., Jansen, J., Levi, M., ten Gate, H., ten Gate, J.W., van Deventer, S.: Regulation of interleukin-10 release by tumor necrosis factor in humans and chimpanzees. J. Exp. Med. 86:2754, 1995
82. Marchant, A., Bruyns, G., Vandenabeele, P., et al.: IL-10 controls INF-gamma and TNF production during experimental endotoxemia. Eur. J. Immunol. 24:1167, 1994
83. Fiorentino, D.F., Zlotnik, A., Mosmann, T.R., Howard, M., O'Garra, A.: IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815, 1991
84. Howard, A., Muchamuel, T., Andrade, S., Menon, S.: Interleukin 10 protects mice from lethal endotoxemia. J. Exp. Med. 177:1205, 1993
85. Gérard, C., Bruyns, C., Marchant, A., et al.: Interleukin-10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J. Exp. Med. 177:547, 1993
86. Chernoff, A E., Granowitz, E.V., Shapiro, L., et al : A randomized, controlled trial of IL-10 in humans: inhibition of inflammatory production and immune responses. J. Immunol. 154:5492, 1995
87. Van der Poll, T., Marchant, A., Buurman, W.A., et al.: Endogenous interleukin-10 protects mice from death during septic peritonitis through a tumor necrosis factor independent mechanism. Surg. Forum 45:18, 1994
88. Greenberger, M.J., Strieter, R.M., Kunkel, S.L., Danforth, J.M., Goodmann, R.E., Standiford, T.J.: Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155:722, 1995
89. Marchant, A., Vincent, J.L., Goldman, M.: Interleukin-10 as a protective cytokine produced during sepsis. In Novel Strategies in the Treatment of Sepsis, D.C. Morrison, J.L. Ryan, editors. 1996, pp. 301-311
90. Han, J., Thompson, F.S., Beutler, B.: Dexamethasone and pentoxifiline inhibit endotoxin induced cachectin tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 172:391, 1990
91. Bernton, E.W., Beach, J.E., Holaday, J.W., Smallridge, R.C., Fein, H.G.: Release of multiple hormones by direct action of interleukin-1 on pituitary cells. Science 230:519, 1987
92. Berkenbosch, F., van Oers, J., del Rey, A., Tilders, F., Besedovsky, H.: Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238:534, 1987
93. Lumpkin, M.D.: The regulation of ACTH secretion by IL-1. Science 235:452, 1987
94. Sapolsky, R., Rivier, C , Yamamoto, G., Plotsky, P., Vale, W : Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 238:522, 1987
95. Bernardini, R., Kamilaris, T.C., Calogero, A.E., et al.: Interactions between tumor necrosis factor-alpha, hypothalamic corticotropin-releasing hormone, and adrenocorticotropin secretion in the rat. Endocrinology 126:2816, 1990
96. Perlstein, R.S., Whithnall, M.H., Abrams, J.S., Mougey, E.H., Neta, R.: Synergistic role of interleukin-6, interleukin-1, and tumor necrosis factor in adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology 132:946, 1993
97. Stouthard, J.M.L., Romjin, J.A., Van der Poll, T., et al.: Endocrinologic and metabolic effects of IL-6 in humans Am. J. Physiol. 268:E819, 1995
98. Chrousos, G.P.: The hypothalamic-pituitary adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 332:1351, 1995
99. Van der Poll, T., Romijin, J.A., Endert, E., Borm, J.J.J., Buller, H.R., Sauerwein, H.P.: Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261. E457, 1991
100. Fischer, E., Marano, M.A., Barber, A.E., et al.: A comparison between effects of interleukin-1 alpha administration and sublethal endotoxemia in primates. Am. J. Physiol. 261:R442, 1991
101. Roh, M.S., Drazenovjich, K.A., Barbose, J J., Dinarello, C.A., Cobb, C.F.: Direct stimulation of the adrenal cortex by interleukin-1. Surgery 102:140, 1987
102. Gwosdow, A R.: Mechanisms of interleukin-1 induced hormone secretion from rat adrenal gland Endocr. Res. 21:25, 1995
103. Gershenwald, J.E., Fong, Y., Fahey, T.F., III, et al.: Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 87:4966, 1990
104. Van Zee, K.J., Coyle, S.M., Calvano, S.E., et al.: Influence of IL-1 receptor blockade on the human response to endotoxinemia. J. Immunol. 154:1499, 1995
105. Remick, D.G., Strieter, R.M., Lynch, J.P., III, Nguyen, D., Eskandari, M., Kunkel, S.L.: In vivo dynamics of murine tumor necrosis factor alpha gene expression. Lab. Invest. 60:766, 1989
106. Pagliacci, M.C., Migliorati, G., Smacchia, M., Grignani, F., Riccardi, C., Nicoletti, I.: Cellular stress and glucocorticoid hormone protect L929 mouse fibroblasts from tumor necrosis factor alpha cytotoxicity. J. Endocrinol. Invest. 16:591, 1993
107. Monick, M.M., Aksamit, T.R., Geist, L.J., Hunninghake, G.W.: Dexamethasone inhibits IL-1 and TNF activity in human lung fibroblasts without affecting IL-1 or TNF receptors. Am. J. Physiol. 267:L33, 1994
108. Molijn, G.J., Spek, J.J., Uffelen, J.C.J., et al.: Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J. Clin. Metab. 80:1799, 1995
109. Barber, A.E., Coyle, S.M., Marano, M.A., et al.: Glucorticoid therapy alters hormonal and cytokine responses to endotoxin in man. J. Immunol. 150:1999, 1993
110. Barber, A.E., Coyle, S.M., Fischer, E., et al.: Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 118:406, 1995
111. Gelin, J.L., Moldawer, L.L., Iresjö, B.M., Lundholm, K.G.: The role of the adrenals in the acute phase response to interleukin-1 and tumor necrosis factor α. J. Surg. Res. 54:70, 1993
112. Rock, C.S., Coyle, S.M., Keogh, C.V., et al.: Influence of hypercortisolemia on the acute-phase response to endotoxin in humans. Surgery 112:467, 1992
113. Van der Poll, T., Jansen, J., Endert, E., Sauerwein, H.P., Van Deventer, S.: Noradrenaline inhibits lipopolysaccharide-induced tumor necrosis factor and interleukin 6 production in human whole blood. Infect. Immun. 62:2046, 1994
114. Van der Poll, T., Braxton, C., Coyle, S.M., et al.: Effect of epinephrine on cytokine release during human endotoxemia. Surg. Forum 46-102, 1995
115. Tracey, K.J., Yuman, F., Hesse, D.G., et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662, 1987
116. Fong, Y., Tracey, K.J., Moldawer, L.L., et al.: Antibodies to cachetin/ tumor necrosis factor reduce interleukin-1 beta and interleukin-6 appearance during lethal bacteremia. J. Exp. Med. 170:1627, 1989
117. Hinshaw, L.B., Emerson, T.E., Taylor, F.B., et al.: Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J. Trauma 33:568, 1992
118. Mohler, K., Torrance, D., Smith, C., et al.: Soluble tumor necrosis factor receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both carriers and TNF antagonists. J. Immunol. 151:1548, 1993
119. Redl, H., Schlag, G., Schiesser, A., Davies, J.: Tumor necrosis factor is a mediator of phospholipase release during bacteremia in baboons. Am. J. Physiol. 264:H119, 1993
120. Shi, Y., Li, H.Q., Shen, C.K., et al.: Association between protective efficacy of antibodies to tumor necrosis factor and suppression of nitric oxide production in neonatal with fatal infection. Pediatr. Res. 34:345, 1993
121. Barton, B., Jackson, J.V.: Protective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect. Immun. 61:1496, 1993
122. Marzi, I., Bauer, M., Secci, A., Bahrami, S., Redi, H., Schlag, G.: Effect of anti-tumor necrosis factor alpha on leukocyte adhesion in the liver after hemorrhagic shock: an intravital microscopic study in the rat. Shock 3:27, 1995
123. Winsor, A.C., Walsh, C.J., Mullen, P.G., et al.: Tumor necrosis factor alpha-blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation. J. Clin. Invest. 91:1459, 1993
124. Vincent, J.L., Bakker, J., Marecaux, G., Schandene, L., Kahan, R., Dupont, E.: Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Chest 101:810, 1992
125. Eskandari, M.K., Bolgos, G., Miller, C., Nguyen, D.T., DeForge, L-E., Remick, D.G.: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxinemia. J. Immunol. 148:2124, 1992
126. Wayte, J., Silva, A., Krausz, T., Cohen, J.: Observations on the role of tumor necrosis factor in a murine model of shock due to Streptococcus pyogenes. Crit. Care Med. 21:1207, 1993
127. Sawyer, R.G., Adams, R.B., May, A.K., Rosenlof, L.K., Pruett, T.L.: Anti-tumor necrosis factor antibody reduces mortality in the presence of antibiotic. Arch. Surg. 128:173, 1993
128. Evans, G.F., Synder, Y.M., Butler, L.D., Zuckerman, S.H.: Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ. Shock 29:279, 1989
129. Bagby, G.J., Plessala, K.J., Wilson, L.A., Thompson, J.J., Nelson, S.: Divergent efficacy of antibody to tumor necrosis factor alpha in intravascular and peritonitis model of sepsis. J. Infect. Dis. 163:83, 1991
130. Zanetti, G., Heumann, D., Gérain, J., et al.: Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice: comparative protective efficacy of antibodies to tumor necrosis factor alpha and to lipopolysaccharide. J. Immunol. 148:1890, 1992
131. Echtenacher, B., Falk, W., Mannel, D.N., Krammer, P.H.: Requirement of endogenous tumor necrosis factor/cachetin for recovery from experimental peritonitis. J. Immunol. 11:165, 1990
132. Mohler, K.M., Sleath, P.R., Fiztner, J.N., et al.: Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature 370:218, 1994
133. Bertini, R., Delgado, R., Faggioni, R., Gascon, M.P., Ythier, A., Ghezzi, P.: Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxin shock. Eur. Cytokine Network 4:39, 1993
134. Haak-Frendsho, M., Marseters, S.A., Mordenti, J., et al.: Inhibition of TNF by a TNF receptor immunoadhesin: comparison to an anti-TNF monoclonal antibody. J. Immunol. 152:1347, 1994
135. Russell, D., Tucken, K.K., Chinookoswoung, N., Thompson, R.C., Kohno, T.: Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: improved survival and organ function. J. Infect. Dis. 171:1538, 1995